Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.

Yang CM, Yoon JC, Park JH, Lee JM.

PLoS One. 2017 Apr 14;12(4):e0175793. doi: 10.1371/journal.pone.0175793. eCollection 2017.

2.

Alterations of the NK cell pool in HIV/HCV co-infection.

Kaczmarek DJ, Kokordelis P, Krämer B, Glässner A, Wolter F, Goeser F, Lutz P, Schwarze-Zander C, Boesecke C, Strassburg CP, Rockstroh JK, Spengler U, Nattermann J.

PLoS One. 2017 Apr 5;12(4):e0174465. doi: 10.1371/journal.pone.0174465. eCollection 2017.

3.

Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.

Asadi-Saghandi A, Shams A, Eslami G, Mirghanizadeh SA, Eskandari-Nasab E.

Virusdisease. 2016 Dec;27(4):369-374. doi: 10.1007/s13337-016-0349-1. Epub 2016 Sep 28.

4.

STAT4-associated natural killer cell tolerance following liver transplantation.

Jamil KM, Hydes TJ, Cheent KS, Cassidy SA, Traherne JA, Jayaraman J, Trowsdale J, Alexander GJ, Little AM, McFarlane H, Heneghan MA, Purbhoo MA, Khakoo SI.

Gut. 2017 Feb;66(2):352-361. doi: 10.1136/gutjnl-2015-309395. Epub 2016 Feb 17.

5.

Spontaneous and natural cytotoxicity receptor-mediated cytotoxicity are effector functions of distinct natural killer subsets in hepatitis C virus-infected chimpanzees.

Verstrepen BE, Nieuwenhuis IG, Mooij P, Bogers WM, Boonstra A, Koopman G.

Clin Exp Immunol. 2016 Jul;185(1):42-9. doi: 10.1111/cei.12774. Epub 2016 Apr 27.

6.

Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Zhou Y, Zhang Y, Moorman JP, Yao ZQ, Jia ZS.

Immunology. 2014 Nov;143(3):319-30. doi: 10.1111/imm.12349. Review.

7.

Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Hu X, Jiang Y, Li X, Gao Y, Guo X, Chi X, Yan H, Feng J, Zhong J, Sun B, Shao X, Xiao W, Pan Y, Niu J.

J Interferon Cytokine Res. 2014 May;34(5):366-75. doi: 10.1089/jir.2013.0049. Epub 2013 Dec 24.

8.

Natural killer cells: multifaceted players with key roles in hepatitis C immunity.

Golden-Mason L, Rosen HR.

Immunol Rev. 2013 Sep;255(1):68-81. doi: 10.1111/imr.12090. Review.

9.

Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection.

Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Stevens M, Schmitt J, Rehermann B.

Hepatology. 2013 Nov;58(5):1621-31. doi: 10.1002/hep.26353. Epub 2013 Sep 30.

10.

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients.

Lv J, Jin Q, Sun H, Chi X, Hu X, Yan H, Pan Y, Xiao W, Tian Z, Hou J, Xu D, Tu Z, Niu J.

Mediators Inflamm. 2012;2012:804043. doi: 10.1155/2012/804043. Epub 2012 Dec 10.

11.

Involvement of activating NK cell receptors and their modulation in pathogen immunity.

Marras F, Bozzano F, De Maria A.

J Biomed Biotechnol. 2011;2011:152430. doi: 10.1155/2011/152430. Epub 2011 Aug 11. Review.

12.

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B.

Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2. doi: 10.1053/j.gastro.2011.06.069. Epub 2011 Jul 7.

13.

KIR/HLA interactions and pathogen immunity.

Jamil KM, Khakoo SI.

J Biomed Biotechnol. 2011;2011:298348. doi: 10.1155/2011/298348. Epub 2011 May 19. Review.

Supplemental Content

Support Center